Typical Antipsychotic international drug patents, generic suppliers and generics

Subscribe to access the full database, or Start Trial
Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Novitium Pharma	THIOTHIXENE	thiothixene	CAPSULE;ORAL	211642-003	Apr 5, 2019	AB	RX	No	Yes	⤷ Start Trial	⤷ Start Trial				⤷ Start Trial
Novitium Pharma	THIOTHIXENE	thiothixene	CAPSULE;ORAL	211642-004	Apr 5, 2019	AB	RX	No	No	⤷ Start Trial	⤷ Start Trial				⤷ Start Trial
Amneal	THIOTHIXENE	thiothixene	CAPSULE;ORAL	215456-001	Feb 28, 2022	AB	RX	No	No	⤷ Start Trial	⤷ Start Trial				⤷ Start Trial
Amneal	THIOTHIXENE	thiothixene	CAPSULE;ORAL	215456-002	Feb 28, 2022	AB	RX	No	No	⤷ Start Trial	⤷ Start Trial				⤷ Start Trial
Amneal	THIOTHIXENE	thiothixene	CAPSULE;ORAL	215456-003	Feb 28, 2022	AB	RX	No	No	⤷ Start Trial	⤷ Start Trial				⤷ Start Trial
Amneal	THIOTHIXENE	thiothixene	CAPSULE;ORAL	215456-004	Feb 28, 2022	AB	RX	No	No	⤷ Start Trial	⤷ Start Trial				⤷ Start Trial
Novitium Pharma	THIOTHIXENE	thiothixene	CAPSULE;ORAL	211642-001	Apr 5, 2019	AB	RX	No	No	⤷ Start Trial	⤷ Start Trial				⤷ Start Trial
>Applicant	>Tradename	>Generic Name	>Dosage	>NDA	>Approval Date	>TE	>Type	>RLD	>RS	>Patent No.	>Patent Expiration	>Product	>Substance	>Delist Req.	>Exclusivity Expiration

Last updated: July 11, 2026

First-generation (typical) antipsychotics are largely off-patent in the US, with most brand exclusivity driven by long-ago pioneer filings and older supplemental patents that have either expired or provide narrow, formulation-specific protection. Competitive entry is therefore less about brand-to-generic exclusivity and more about (1) line-extension patents for specific salts, dosage forms, or release profiles, (2) US exclusivity for newly submitted generic NDAs and 505(b)(2) reformulations where relevant, (3) patent fences around long-acting injectables, and (4) product-level manufacturing and bioequivalence strategy.

Where patent walls still exist, they tend to be narrow and jurisdiction-specific, concentrated in long-acting depot formulations and fixed-dose combinations rather than core active pharmaceutical ingredients (APIs). As a result, market dynamics center on supply, drug shortages, formulation continuity, payer contracting, and substitution rather than breakthrough IP.

Which patents protect first-generation antipsychotics (typical antipsychotics) in the US?

Answer: In the US, most protection for typical antipsychotics is historical and largely expired for the classic APIs (chlorpromazine, haloperidol, fluphenazine, trifluoperazine, thioridazine, perphenazine). Remaining patent coverage, where present, is usually limited to specific formulation versions, dosage strengths, or (for some agents) long-acting depot delivery systems.

Core API patents: mostly expired

Classic first-generation antipsychotics entered the market decades ago. Pioneer composition-of-matter terms have generally expired, and the current patent estate is dominated by:

formulation patents (polymorph/crystal form, salt form, excipient system),
manufacturing-process patents for specific solid forms or injectables,
device-related or container-closure system patents for selected products, and
method-of-use patents that may or may not have commercial linkage depending on FDA label scope.

Depot and sustained-release patents: the main “live” category

Long-acting injectables and sustained-release versions can retain patent protection longer than oral immediate-release tablets, especially when a specific depot platform was reformulated after the pioneer era. For typical antipsychotics, patent risk concentrates on:

specific ester/decanoate formulations (where applicable by agent),
particle size and reconstitution stability,
sterile manufacturing controls for depot suspensions, and
injectable packaging and administration systems.

Orange Book mechanics: what matters for enforcement

For typical antipsychotics, enforcement risk is typically not from “generic entry” against API claims but from Orange Book-listed patents tied to a branded NDA. Generic challenges (Paragraph IV) are usually aimed at formulation or method-of-use patents listed for the reference drug. If no Orange Book patents remain, the launch path is “at risk” only in a non-Orange-Book sense (state law, unlisted patents, or later-identified patents).

How many Orange Book-listed patents cover chlorpromazine and what formulations are protected?

Answer: Chlorpromazine’s branded landscape in the US is largely mature and mostly off-patent for API-level claims; any remaining patent coverage is typically formulation-specific (e.g., particular tablet strengths, specific injectable/solution presentations, or depot-related versions if present for a given product).

Formulation clusters to map for freedom to operate

For chlorpromazine, patent-relevant product variants generally fall into:

oral solid immediate-release presentations (tablets/dragees/solutions),
oral concentrate or solution formulations (excipients, stability, concentration),
injectable dosage forms (solutions, reconstitution requirements for any suspension),
any specific brand-specific strength and packaging.

Litigation pattern expectation

For classic antipsychotics, settlement and dismissal patterns often reflect:

generic approval after expiration of listed patents, or
“carve-out” of non-infringing strengths/forms, rather than sustained PI/FOA injunction campaigns.

What patents protect haloperidol and when do they lose exclusivity?

Answer: Haloperidol is generally off-patent at the API level in the US. Remaining exclusivity, when it exists for branded products, is usually tied to specific formulation presentations and may have already lapsed for the major legacy brands.

Where exclusivity can still matter commercially

Even if the API is free, market access can be impacted by:

a branded depot suspension with a later reformulation history,
a 505(b)(2) reformulation of a specific haloperidol product with a narrower patent linkage,
remaining listed patents on a single NDA that can delay a generic manufacturer at the product level.

Regulatory timing variables

Generic entry depends on Orange Book patent status and FDA’s assessment of whether a proposed generic product is bioequivalent and pharmaceutically equivalent to a protected reference listed drug. Depot suspensions often face more practical manufacturing constraints, affecting actual launch timing.

Which first-generation antipsychotics still have meaningful patent fences for long-acting injectables?

Answer: The highest residual patent relevance in typical antipsychotics is in long-acting depot products, where formulation, suspension characteristics, and sterile manufacturing can be protected by narrower patents that may remain in force longer than oral immediate-release.

Depot delivery system patent themes

Depot antipsychotic patents often cover:

ester concentration and suspension rheology,
particle size distribution and sedimentation control,
reconstitution and stability post-mixing,
sterilization, aseptic filling and lyophilization/reconstitution steps,
device-to-drug integration (where applicable).

Commercial risk implication

Even if a generic “can” launch on paper, depot sterile supply chain and QA validation can become the binding constraint. When patent barriers persist, they usually do so for a specific branded depot presentation rather than across the entire class.

How strong is the patent estate for typical antipsychotics (chlorpromazine, haloperidol, trifluoperazine, fluphenazine, thioridazine, perphenazine)?

Answer: Patent estate strength is typically low at the API level and moderate at the product/formulation level for select presentations. The practical enforcement surface is small: Orange Book-listed patents, fewer active method-of-use claims tied to current labels, and a history of long-running “mature generics” competition that has already absorbed most patent friction.

Strength scorecard (industry-standard framing)

For typical antipsychotics, the estate tends to score as:

Composition-of-matter (API): expired for most products.
Formulation: low to medium, presentation-dependent.
Method-of-use: low to medium; depends on label and whether a listed patent exists for that label.
Process/manufacturing: low to medium; often relevant only if a generic uses a substantially different manufacturing method.
Device/container: low; usually limited to specific branded configurations.

What is the Paragraph IV (Hatch-Waxman) litigation risk for typical antipsychotic generics?

Answer: Paragraph IV risk is generally lower for classic oral typical antipsychotics because the core API patents are long expired and the Orange Book patent lists have often cleared. When risk exists, it concentrates around specific branded products with remaining listed formulation patents and around depot or specialized formulations.

Typical litigation outcomes in mature classes

In mature first-generation antipsychotic classes, litigation tends to resolve through:

early dismissals after patent expiry,
non-infringement or invalidity determinations tied to narrow formulation claims,
settlements that align with product launch timing rather than prolonged injunctive relief.

How does exclusivity work for first-generation antipsychotics in the US (patents, 3/5-year exclusivity, and orphan where relevant)?

Answer: For the classic typical antipsychotics, marketing exclusivity (3-year new clinical investigation or 5-year new chemical entity) is largely irrelevant to current branded products. The active lever for delay today is Orange Book patent status for listed formulations, not statutory exclusivity.

What to check in practice

Whether the reference drug’s Orange Book lists patents tied to the currently marketed strength/form.
Whether those patents have already expired or are nearing expiry.
Whether a 505(b)(2) reformulation exists for a given brand, creating a different listing profile than the legacy API product.

What formulations are protected for fluphenazine, and do depot products change the IP picture?

Answer: Fluphenazine’s market relevance includes both oral forms and depot products in some markets. In the US, patent relevance persists mostly for specific product presentations, with any stronger fences concentrated in depot formulations rather than oral immediate-release tablets.

Depot vs oral patent linkage

Depot: higher chance of active formulation or manufacturing claims on specific branded depot suspensions.
Oral: lower residual patent relevance; competition is typically extensive with multiple generics.

How does trifluoperazine’s patent landscape compare with perphenazine and thioridazine?

Answer: Comparable dynamic across these typical antipsychotics: API-level patents are largely expired, and remaining protection is presentation-specific. Patent significance is typically higher where a branded depot or specialized formulation exists.

Relative practical risk

Lower risk: oral immediate-release tablets and well-established generics.
Higher risk: depot or specialized presentations, especially where Orange Book lists multiple patents tied to a single NDA and product.

Which companies are positioned to launch generics for typical antipsychotics fastest, and what drives timing?

Answer: Timing is primarily driven by (1) Orange Book clearance for the specific reference product and presentation, (2) supply chain ability to meet FDA chemistry, manufacturing, and controls requirements for the chosen dosage form, and (3) payer substitution dynamics and wholesaler stocking behavior.

What drives the practical launch calendar

Patent expiry dates for listed patents on the specific NDA/strength.
FDA review and inspection schedules (especially sterile injection lines).
Bioequivalence study feasibility (oral vs depot).
Product continuity and drug shortage history that affects urgency and priority review.

What generic entry risks exist for at-risk launches in typical antipsychotics?

Answer: For typical antipsychotics, the main “at-risk” risk is not from broad API injunctions but from:

overlooked Orange Book patents tied to specific strengths/forms,
unlisted patents asserted separately under state law,
and supply-form mismatch where a “formally approved” generic does not map to the intended marketed presentation.

Risk hotspots

depot suspensions and sterile injectables
branded strengths that have unique listed patents
reformulations with narrow but enforceable formulation claims

How do 505(b)(2) reformulations and line extensions affect the patent landscape for typical antipsychotics?

Answer: 505(b)(2) reformulations can reintroduce patent-driven differentiation without reviving API-level exclusivity. The resulting Orange Book profile can be different from that of the legacy NDA, adding incremental barriers at the product level.

Where this shows up

reformulated release (where applicable)
new excipient system or stability-enhanced versions
dosage form changes that still rely on the reference drug for certain data

Which jurisdictions besides the US matter for enforcement in first-generation antipsychotics?

Answer: For global commercialization, enforcement focus typically shifts to:

EU SPC and national phase formulation patents where applicable,
UK post-Brexit patent and data exclusivity rules for SPC,
Canada’s PM(NOC) linkage tied to listed patents on referenced drug products,
and key Asian markets where patent enforcement varies by jurisdiction and product registration pipeline.

Global market consequence

Even when US freedom to operate is cleared, other jurisdictions can still block commercialization of a specific presentation, especially depot formulations with active local patents.

Market dynamics: how do drug shortages, payer contracting, and substitution shape typical antipsychotic sales?

Answer: In typical antipsychotics, demand is stable but product-level availability and payer policies determine realized sales more than marketing differentiation.

Key market drivers

generic substitution economics: lowest-cost, contracted suppliers dominate
wholesaler stocking and shortage-driven temporary pricing
brand persistence in certain formularies tied to patient history or switching restrictions
supply stability in sterile injection segments (if relevant)

Key patent-to-commercial “playbook” for typical antipsychotics

Answer: For typical antipsychotics, an actionable IP workflow focuses on product presentation and Orange Book mapping, not API-level sweeping searches.

Actionable diligence checklist

Identify the exact marketed reference product(s) by NDA and strength.
Pull Orange Book listings and isolate patent types: composition, formulation, method-of-use, process, and any depot-related patents.
Determine the expiry schedule for each listed patent (including any disclaimers/terminal disclaimers if used in the underlying patents).
Map the planned generic product’s pharmaceutical equivalence and dosage form to the patented claim scope.
For depot products or sterile injectables, add manufacturing process differentiation analysis to reduce risk under process-manufacturing claims.
Review history of Paragraph IV challenges for the exact reference drug and presentation to estimate settlement likelihood and launch timing.

Key Takeaways

Typical antipsychotics have largely cleared API-level exclusivity in the US; remaining patent barriers are usually narrow and formulation or presentation specific.
Patent relevance is highest for long-acting depot products and specific sterile injectables where formulation and manufacturing claims can persist.
Paragraph IV litigation risk is generally lower for mature oral typical antipsychotics, but it concentrates where Orange Book listings still include enforceable formulation or method-of-use patents tied to the marketed NDA and strength.
Market dynamics depend more on payer contracting, substitution, drug availability, and supply-chain capability than on ongoing brand differentiation.

FAQs

1) What Orange Book patents matter most for generic chlorpromazine tablets versus injectable formulations?
Answer: The patents tied to the specific NDA strength and dosage form, especially any listed formulation or manufacturing patents for the injectable product line.

2) Can a generic launch be blocked by an unlisted patent in typical antipsychotics?
Answer: Yes, via non-Orange-Book patent assertions under applicable law, though most market delay in the class is driven by Orange Book-listed patents.

3) Do method-of-use patents for typical antipsychotics still affect generic approval?
Answer: They can if they are listed in the Orange Book for the reference drug and are within claim scope aligned to the proposed generic’s label and use.

4) How do depot formulations change the bioequivalence and patent risk profile for typical antipsychotics?
Answer: Depot suspensions often increase manufacturing and stability complexity, creating more presentation-specific patent leverage and practical CMC constraints.

5) What drives settlement timing for Paragraph IV challenges in mature antipsychotic classes?
Answer: Patent expiry proximity for the exact listed patents, narrowness of formulation claims, and the ability for the generic to switch strengths/forms or launch another presentation.

References (APA)

No sources were provided in the prompt, and no cited factual patent or FDA product data can be generated accurately without specific drug/NDA/patent identifiers.